BioCryst FDA ok for ORLADEYO 150 mg oral pellets as once-daily hereditary angioedema prophylaxis

 

BioCryst wins FDA approval for ORLADEYO 150 mg oral pellets as once-daily hereditary angioedema prophylaxis for patients 12 and older

• FDA approval covers supplemental NDA for ORLADEYO 150 mg oral pellets, expanding the drug’s approved U.S. formulations.

https://finviz.com/stock?t=BCRX&p=d